Tirzepatide typically starts at 2.5 mg once weekly for four weeks, then increases by 2.5 mg increments every 4 weeks as tolerated, up to a maximum of 15 mg weekly
When cells undergo mitosis, the process that normally leads to perfect duplication and distribution of chromosomal information to each cell, vulnerable chromosomes can get pulled apart and fragments mismatched, leading to misinformation
This is why many providers, and many patients, transition to the 20mg/mL concentration as doses increase
Semaglutide (the drug in Wegovy) is a long-acting medication that starts at a lower dose to minimise side effects as it builds up to the full maintenance dose
However, this model may not fully reflect the complexity of diabetes in patients
Notably, both liver IRI and kidney IRI are significantly reduced by the ferroptosis inhibitor liproxstatin-1 (Lip-1), suggesting that ferroptosis plays an important pathogenic role in IRI [4]